EQL has entered into an exclusive license agreement for its product Mellozzan (melatonin) with Adalvo Ltd. for 89 countries outside Europe and the USA. Among the countries are large markets such as China, Brazil, Canada, Egypt and Japan. The agreement gives Adalvo exclusive rights to register, commercialise and distribute Mellozzan in these countries.

If Adalvo decides to not pursue some countries the rights to Mellozzan for those specific countries shall be returned to EQL in a pre-defined reasonable timeframe. EQL Pharma act as manufacturer and supplier of Mellozzan for all third-party agreements signed by Adalvo on Mellozzan. The agreement also includes license income for signing certain individual key markets, as well as a profit sharing on future sales of Mellozzan.

Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Melatonin is widely used for sleep problems throughout the world, but the ADHD paediatric indication Mellozzan has does not exist for any melatonin medicine outside of Europe. Mellozzan is also indicated for the short-term treatment of jet lag in adults.